Pfizer brings InnoPharma into the fold
- Pfizer has agreed to acquire privately held InnoPharma for $225 million in cash and another $135 million in potential milestone payments.
- InnoPharma has 10 FDA-approved generics on the market and another 19 products in the pipeline.
- The deal, expected to close in Q3, is contingent on regulatory approval.
In addition to the products that InnoPharma has already filed with FDA, the company also has more than 30 injectable and ophthalmic products under development. Some of the areas in which InnoPharma excels include development of novel formulations of existing drugs, including situations whether there are challenges related to manufacturing or bioequivalence.
According to John Young, group president, Pfizer Global Established Pharma, “InnoPharma’s "InnoPharma's technical capabilities in bringing complex generics to market, coupled with its strong talent and product pipeline, build on our efforts to develop and commercialize critically important medicines for the patients who need them."
- World Pharma News Pfizer to acquire InnoPharma